Options IT Expands the PIPE Velocity Managed Service for High-Frequency Trading to ISE’s Data Centers
PIPE Velocity Expansion Comes as ISE Prepares for April Debut of new Optimise TM Trading System
Options IT , a leading provider of ultra-low latency market data and connectivity, fully managed application hosting, and high-performance technology Infrastructure-as-a-Service (IaaS) for the buyside and sellside, today announced it has expanded its PIPE Velocity service for high-frequency trading firms to provide access to the International Securities Exchange’s (ISE) new Optimise™ trading platform and full suite of market data offerings.
The expansion of the PIPE Velocity service comes as ISE prepares for the rollout of its new Optimise trading platform in April. Optimise is expected to be a leader among US options exchanges with regard to latency and performance.
PIPE Velocity is a complete HFT technology solution, providing ultra-low latency market data, high throughput market connectivity and vendor neutral application hosting as a single, fully managed service for all available major markets across North America, Europe and Asia.
“The reduced latency and increased throughput and capacity anticipated with the launch of ISE’s new trading platform provides a significant opportunity for traders that incorporate speed of execution into their strategies,” said Nigel Kneafsey, CEO of Options IT. “We anticipate ISE’s new platform will lead to a general increase in overall options trading volume as new trading opportunities often arise from these types of significant system upgrades.”
“We are very pleased that Options IT, with its full suite of managed technology services, will be able to provide firms with efficient, low latency access to the full range of ISE’s market data products,” said Jeff Soule, Head of Market Data at ISE.
PIPE Velocity is one of three services offered on the Options PIPE® platform , a fully managed and optimized global technology infrastructure and network connectivity environment providing on-demand, private cloud technology solutions to more than 120 investment banks, proprietary trading shops, brokerages, and traditional and alternative asset management firms globally.
###
About ISE (www.ise.com ):
The International Securities Exchange (ISE) operates a leading U.S. options exchange and offers options trading on over 2,000 underlying equity, ETF, index, and FX products. As the first all-electronic options exchange in the U.S., ISE transformed the options industry by creating efficient markets through innovative market structure and technology. Regulated by the Securities and Exchange Commission (SEC) and a member-owner of The Options Clearing Corporation (OCC), ISE provides investors with a transparent marketplace for price and liquidity discovery on centrally cleared options products. ISE continues to expand its marketplace through the ongoing development of enhanced trading functionality, new products, and market data services.
ISE is a wholly owned subsidiary of Eurex, a leading global derivatives exchange. Eurex itself is jointly operated by Deutsche Börse AG (Ticker: DB1) and SIX Swiss Exchange AG. Together, Eurex and ISE are the global market leader in individual equity and equity index derivatives.
About Options IT (www.options-it.com ):
Options IT is the provider of the global Options PIPE private financial cloud services platform, delivering ultra-low latency market data, connectivity and fully managed application hosting services to the banking, trading and investment community. Combining innovative technology solutions with highly experienced technology management and support staff, the Options PIPE® platform, provides a complete financial technology infrastructure as a pay-as-you-go service. The Options PIPE platform delivers the scalability, strength and security of an enterprise platform with the efficiencies of a hosted solution.
Contact:
For additional information
:
International Securities Exchange
Molly
H. McGregor, 212-897-0275
mmcgregor@ise.com
or
Patrick
Ruppe, 646-205-2500
Head of Marketing, Options IT
patrick.ruppe@options-it.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%18.6.2025 03:20:00 CEST | Press release
- To accommodate large-scale TVs and high-end model demands - Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 20301 on an area basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613720341/en/ Image of Mihara Plant [Features] Facilitates the efficient manufacture, or imposition, of high fun
Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce18.6.2025 02:27:00 CEST | Press release
Over 250,000 units of Rokid Glasses have already been ordered, integrated with Alipay’s digital payment technology for AR glasses.The integration of payments into AR glasses supports a future of seamless, intuitive commerce—enabling instant, gesture-based transactions, immersive product discovery, and new ways for businesses to engage customers. Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/ Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities. According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom